Search Within

Zhigang Zhang

  1. "Sarcoma Service"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Biostatistics Service (6)
  2. Department of Medicine (6)
  3. Epidemiology and Biostatistics (6)
  4. Sarcoma Service (6)
  5. Solid Tumor Oncology Division (6)
  6. Center for Hematologic Malignancies (5)

More Groups

People
  1. Kaled Alektiar (3)
  2. Sandra D'Angelo (3)
  3. Suzanne Wolden (3)
  4. Abraham Wu (2)
  5. Andreas Rimner (2)
  6. Andrew Zelenetz (2)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2017 (1)
  5. 2013 (2)
Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2)
  2. Radiotherapy and Oncology (2)
  3. Blood (1)
  4. Clinical Cancer Research (1)
Publishers
  1. Elsevier Inc. (4)
  2. American Association for Cancer Research (1)
  3. American Society of Hematology (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Journal Article

    Barker, C. A.; D'Angelo, S. P.; Wasilewski, G.; Steckler, A. M.; Lian, M.; Zhang, Z.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Radiotherapy and Oncology (2024)

    Fulltext@MSK | Save
  • Stereotactic body radiation therapy for sarcoma pulmonary metastases
    Journal Article

    Lebow, E. S.; Lobaugh, S. M.; Zhang, Z.; Dickson, M. A.; Rosenbaum, E.; D'Angelo, S. P.; Nacev, B. A.; Shepherd, A. F.; Shaverdian, N.; Wolden, S.; more...
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Stereotactic body radiotherapy for sarcoma pulmonary metastases
    Meeting Abstract

    Lebow, E. S.; Lobaugh, S.; Zhang, Z.; Dickson, M.; Thornton, K.; Rosenbaum, E.; D'Angelo, S.; Nacev, B.; Shepherd, A. F.; Shaverdian, N.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • ABT-888 plus bendamustine is safe and has shown preliminary efficacy in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Schwartz, G. K.; Carvajal, R.; Fury, M.; Konner, J.; Hyman, D. M.; Gounder, M.; Gajria, D.; Teitcher, J.; Zhang, Z.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols
    Journal Article

    Gerber, N. K.; Wexler, L. H.; Singer, S.; Alektiar, K. M.; Keohan, M. L.; Shi, W.; Zhang, Z.; Wolden, S.
    International Journal of Radiation Oncology, Biology, Physics (2013)

    Fulltext@MSK | Save